Abstract
Myeloid leukaemia cells are sensitive to attack by elements of the immune system as evidenced by the effects of T cell depletion, graft versus leukaemia and donor lymphocyte infusion on leukaemic recurrence. An implication is that the immune system can be manipulated to enhance anti-leukaemic effects by exogenous stimulation including the use of immunostimulatory cytokines. These could potentially be used in a controlled manner that avoids the clinical problems associated with graft-versus-host disease. The cytokine used most extensively to date is interleukin-2 (IL2), a molecule that induces T lymphocyte proliferation and the generation of MHC unrestricted cytotoxicity. Despite over 10 years of clinical experience, the data on efficacy in acute myeloid leukaemia remains unclear due to lack of adequate randomised trials. IL2 appears to be effective in patients with low level marrow infiltration by acute myeloid leukaemia (AML) blast cells. It is less effective when patients present or relapse with packed bone marrows. The logical assumption that IL2 treatment given during states of minimal residual disease will reduce the incidence or speed of disease recurrence remains to be adequately tested. IL2 administration is associated with characteristic clinical adverse effects and with specific immuno-haematological changes. The use of other cytokines for immune manipulation in patients with AML is so far essentially limited to the research laboratory. Potential uses include cytokine induced blast differentiation to dendritic cells and the use of irradiated cytokine gene transduced leukaemic cells as vaccines.
Keywords: human acute leukaemia, cytotoxicity
Current Pharmaceutical Design
Title: Cytokine Manipulation of the Immune Response in the Treatment of Human Acute Leukaemia
Volume: 8 Issue: 5
Author(s): David Gottlieb
Affiliation:
Keywords: human acute leukaemia, cytotoxicity
Abstract: Myeloid leukaemia cells are sensitive to attack by elements of the immune system as evidenced by the effects of T cell depletion, graft versus leukaemia and donor lymphocyte infusion on leukaemic recurrence. An implication is that the immune system can be manipulated to enhance anti-leukaemic effects by exogenous stimulation including the use of immunostimulatory cytokines. These could potentially be used in a controlled manner that avoids the clinical problems associated with graft-versus-host disease. The cytokine used most extensively to date is interleukin-2 (IL2), a molecule that induces T lymphocyte proliferation and the generation of MHC unrestricted cytotoxicity. Despite over 10 years of clinical experience, the data on efficacy in acute myeloid leukaemia remains unclear due to lack of adequate randomised trials. IL2 appears to be effective in patients with low level marrow infiltration by acute myeloid leukaemia (AML) blast cells. It is less effective when patients present or relapse with packed bone marrows. The logical assumption that IL2 treatment given during states of minimal residual disease will reduce the incidence or speed of disease recurrence remains to be adequately tested. IL2 administration is associated with characteristic clinical adverse effects and with specific immuno-haematological changes. The use of other cytokines for immune manipulation in patients with AML is so far essentially limited to the research laboratory. Potential uses include cytokine induced blast differentiation to dendritic cells and the use of irradiated cytokine gene transduced leukaemic cells as vaccines.
Export Options
About this article
Cite this article as:
Gottlieb David, Cytokine Manipulation of the Immune Response in the Treatment of Human Acute Leukaemia, Current Pharmaceutical Design 2002; 8 (5) . https://dx.doi.org/10.2174/1381612023396087
DOI https://dx.doi.org/10.2174/1381612023396087 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
FLT3 Inhibitors in the Management of Acute Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry Targeting of Leukemia-Initiating Cells to Develop Curative Drug Therapies: Straightforward but Nontrivial Concept
Current Cancer Drug Targets Going 3D – Cell Culture Approaches for Stem Cell Research and Therapy
Current Tissue Engineering (Discontinued) The Role of microRNAs in the Pathogenesis and Treatment of Hematopoietic Malignancies
Current Pharmaceutical Design Paraneoplastic Pemphigus: Autoimmune-Cancer Nexus in the Skin
Anti-Cancer Agents in Medicinal Chemistry Application of Stem Cell Therapy During the Treatment of HIV/AIDS and Duchenne Muscular Dystrophy
Current Stem Cell Research & Therapy The Disulfide Analogues of Isophosphoramide Mustard for Anticancer Therapy
Letters in Drug Design & Discovery Revisiting Non-Cancer Drugs for Cancer Therapy
Current Topics in Medicinal Chemistry Serum Proteomics in the Diagnosis and Treatment of Haematological Malignancies
Current Proteomics Progress in the Development of Selective Inhibitors of Aurora Kinases
Current Topics in Medicinal Chemistry Two Promising Anti-Cancer Compounds, 2-Hydroxycinnaldehyde and 2- Benzoyloxycinnamaldehyde: Where do we stand?
Combinatorial Chemistry & High Throughput Screening Annexins in the Central Nervous System: Are they Neuroprotective or Proapoptotic Agents?
Medicinal Chemistry Reviews - Online (Discontinued) System Models, Assays and Endpoint Parameters to Evaluate Anticancer Compounds During Preclinical Screening
Current Medicinal Chemistry The Adipose Tissue as a Source of Vasoactive Factors
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Chemokine Receptors as Targets for Cancer Therapy
Current Pharmaceutical Design The Role of Foxp3 in Regulatory T Cell Differentiation and Function
Current Immunology Reviews (Discontinued) Epigenetic Modifications as Therapeutic Targets
Current Drug Targets State-of-the-Art Lentiviral Vectors for Research Use: Risk Assessment and Biosafety Recommendations
Current Gene Therapy Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and New Therapeutic Perspectives in Non Small Cell Lung Cancer
Current Drug Targets Treatment of Acute Leukaemias with Monoclonal Antibodies: Current Status and Future Prospects
Cardiovascular & Hematological Agents in Medicinal Chemistry